Performance of Human Immunodeficiency Virus Type 1 Gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2006 Sep 7

PMID 16954280

Citations 4

Authors

Michelle Marcial

Jing Lu

Steven G Deeks

Rainer Ziermann

Daniel R Kuritzkes

Affiliations

Soon will be listed here.

Abstract

The performance of a gp41 assay, created using reagents designed for use with the OpenGene DNA Sequencing System, was evaluated using a panel of plasma samples obtained from enfuvirtide-naive and -experienced human immunodeficiency virus type 1-infected subjects. Resulting sequence data were highly accurate compared to a "home brew" assay and clonal sequence analysis.

Citing Articles

Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.

Smith M, Hoffman J, Sojar H, Aalinkeel R, Hsiao C, Hicar M Curr HIV Res. 2019; 16(6):404-415.

PMID: 30836922 PMC: 6710457. DOI: 10.2174/1570162X17666190228154850.

Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.

Leung M, Cohen F Biophys J. 2011; 100(8):1960-8.

PMID: 21504732 PMC: 3077694. DOI: 10.1016/j.bpj.2011.02.053.

Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Morozov V, Morozov A, Lagaye S AIDS Res Hum Retroviruses. 2010; 26(1):73-7.

PMID: 20055586 PMC: 2858901. DOI: 10.1089/aid.2009.0079.

HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.

Becker Y Virus Genes. 2007; 34(3):233-40.

PMID: 17333401 DOI: 10.1007/s11262-007-0082-3.

References

Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis J . Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001; 39(4):1254-7. PMC: 87920. DOI: 10.1128/JCM.39.4.1254-1257.2001. View

Grant R, Kuritzkes D, Johnson V, Mellors J, Sullivan J, Swanstrom R . Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003; 41(4):1586-93. PMC: 153856. DOI: 10.1128/JCM.41.4.1586-1593.2003. View

Kuritzkes D, Grant R, Feorino P, Griswold M, Hoover M, Young R . Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003; 41(4):1594-9. PMC: 153857. DOI: 10.1128/JCM.41.4.1594-1599.2003. View

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes D . Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol. 2004; 78(9):4628-37. PMC: 387671. DOI: 10.1128/jvi.78.9.4628-4637.2004. View

Sista P, Melby T, Davison D, Jin L, Mosier S, Mink M . Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS. 2004; 18(13):1787-94. DOI: 10.1097/00002030-200409030-00007. View

Marcelin A, Reynes J, Yerly S, Ktorza N, Segondy M, Piot J . Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS. 2004; 18(9):1340-2. DOI: 10.1097/00002030-200406180-00015. View

Wild C, Shugars D, Greenwell T, McDanal C, Matthews T . Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994; 91(21):9770-4. PMC: 44898. DOI: 10.1073/pnas.91.21.9770. View

Rimsky L, Shugars D, Matthews T . Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998; 72(2):986-93. PMC: 124569. DOI: 10.1128/JVI.72.2.986-993.1998. View

10.

Kilby J, Hopkins S, Venetta T, DiMassimo B, Cloud G, Lee J . Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998; 4(11):1302-7. DOI: 10.1038/3293. View

11.

Xu L, Pozniak A, Wildfire A, Stanfield-Oakley S, Mosier S, Ratcliffe D . Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother. 2005; 49(3):1113-9. PMC: 549241. DOI: 10.1128/AAC.49.3.1113-1119.2005. View

12.

Mink M, Mosier S, Janumpalli S, Davison D, Jin L, Melby T . Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. 2005; 79(19):12447-54. PMC: 1211558. DOI: 10.1128/JVI.79.19.12447-12454.2005. View

13.

Halvas E, Aldrovandi G, Balfe P, Beck I, Boltz V, Coffin J . Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol. 2006; 44(7):2612-4. PMC: 1489464. DOI: 10.1128/JCM.00449-06. View

14.

Lu J, Deeks S, Hoh R, Beatty G, Kuritzkes B, Martin J . Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006; 43(1):60-4. DOI: 10.1097/01.qai.0000234083.34161.55. View